“This reinforces the positive impact of triple therapy on patients with asthma uncontrolled on inhaled corticosteroids/long-acting beta agonists and provides us with further evidence that this treatment should be used in this patient population,” Njira L. Lugogo, MD, associate professor of internal medicine and director of the division of pulmonary and critical care medicine’s asthma program at Michigan Medicine, told Healio.
"In addition, this can be implemented in primary care where a large proportion of poorly controlled patients seek care. It is also important to note that the high dose triple combination therapy has a medium dose ICS which is important as we embrace ICS stewardship and avoid long term use of high dose ICS. In addition, unlike COPD the asthma triple includes a higher dose of glycopyrrolate due to the higher lung function that was achieved on this dose."